Concentration effect relationship of CYP3A inhibition by ritonavir in humans

Eur J Clin Pharmacol. 2013 Oct;69(10):1795-800. doi: 10.1007/s00228-013-1530-8. Epub 2013 Jun 9.

Abstract

Purpose: To investigate the dose and concentration dependency of CYP3A inhibition by ritonavir using the established limited sampling strategy with midazolam for CYP3A activity.

Methods: An open, fixed-sequence study was carried out in 12 healthy subjects. Single ascending doses of ritonavir (0.1-300 mg) were evaluated for CYP3A inhibition in two cohorts using midazolam as a marker substance.

Results: Ritonavir administered as a single oral dose produced a dose-dependent CYP3A inhibition with an ID50 of 3.4 mg. Using the measured ritonavir concentrations an exposure-inhibition effect curve was established with an IC50 of 600 h pmol/L (AUC2-4). Over the ritonavir dose range studied non-linear exposure of ritonavir was observed.

Conclusions: Ritonavir shows a dose and concentration effect relationship of CYP3A inhibition. In addition, a proposed auto-inhibition of ritonavir metabolism resulted in a non-linear exposure of ritonavir with sub-proportional concentrations at low doses. A time-dependent CYP3A activity may result when inhibitors of CYP3A with short elimination half-lives are used.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Area Under Curve
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 CYP3A Inhibitors*
  • Dose-Response Relationship, Drug
  • Female
  • HIV Protease Inhibitors / administration & dosage*
  • HIV Protease Inhibitors / blood
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Male
  • Midazolam / administration & dosage
  • Midazolam / blood
  • Midazolam / pharmacology
  • Middle Aged
  • Nontherapeutic Human Experimentation
  • Ritonavir / administration & dosage*
  • Ritonavir / blood
  • Ritonavir / pharmacology*
  • Young Adult

Substances

  • Cytochrome P-450 CYP3A Inhibitors
  • HIV Protease Inhibitors
  • CYP3A protein, human
  • Cytochrome P-450 CYP3A
  • Ritonavir
  • Midazolam